GLP-1 & Metabolic Optimization
Branded weight management, transparently priced
Branded Wegovy®, Zepbound®, and Mounjaro® dispensed through a separately licensed retail/specialty pharmacy partner at the dispensing pharmacy's published cash price. Mon Élan does not add a markup to medication. Compounded GLP-1 — only when a documented per-patient clinical difference cannot be met by the branded product — is dispensed through a separate licensed 503A compounding pharmacy partner.
“Every protocol on this page is governed by our Medical Director and reviewed against current evidence. Mon Élan is a clinical practice — not a refill form.”
What we treat in this protocol.
Mon Élan is a medical practice, not a marketplace. Whether a compounded therapy is appropriate — and which one — is a clinical decision made by your physician at the encounter, under documented clinical decision-making and titrated against your labs.
Semaglutide
Chronic weight management; type-2 diabetes (where clinically indicated)
Tirzepatide
Chronic weight management; type-2 diabetes
Important safety information
GLP-1 receptor agonists, including semaglutide (the active ingredient in branded products such as Wegovy® and Ozempic®), tirzepatide (Zepbound® and Mounjaro®), and liraglutide (Saxenda® and Victoza®), carry an FDA boxed warning for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Additional clinically significant warnings include acute pancreatitis, gallbladder disease, hypoglycemia (particularly when combined with insulin or sulfonylureas), acute kidney injury, and potential worsening of diabetic retinopathy in patients with type 2 diabetes. A Mon Élan physician will review your complete medical history, current medications, and family history before determining whether GLP-1 therapy is clinically appropriate.
Talk to a Mon Élan physician about whether GLP-1 therapy is right for you.
What you can expect.
Every Mon Élan protocol begins with a video consultation with a licensed clinician and a review of your baseline labs. From there, the protocol is titrated against your response — not against a population average.
Universal intake & baseline labs
8-minute clinical assessment with universal safety screening (PHQ-2, GAD-2, C-SSRS). Baseline lab panel ordered immediately on enrollment — drawn at a contracted lab partner near you.
Physician consultation
Video visit with your prescribing physician within 24-48 hours of intake completion. Lab review, protocol design, prescription routing through your Patient Dashboard.
Titration and follow-up labs
Every protocol titrates over 4-12 weeks based on tolerability and labs. Follow-up lab panel at week 6-8, then quarterly. Async messaging with your physician anytime.
Cross-vertical coordination
Your Unified Patient Record makes coordination structural. Mandatory drug-interaction screening before every prescription change, across every vertical.
Peptide Therapy
Compounded peptide therapy, prescribed by a Mon Élan-affiliated physician when clinically appropriate for your case and titrated against your labs. The specific compound, dose, and titration are determined at the encounter — not from a marketplace menu.
One transparent rate. No surprise bills.
Your monthly membership covers everything Mon Élan provides. Medications are dispensed by a separately licensed 503A compounding pharmacy partner (for compounded preparations) or a separately licensed retail/specialty pharmacy partner (for branded FDA-approved products), at the dispensing pharmacy’s published cash price. Mon Élan does not add a markup to medication.
Begin with a clinical encounter, not a checkout.
Your assessment takes eight minutes. A licensed provider reviews it within 24 hours. No charge to begin.
Begin assessment